Trial Profile
A Randomized, Double-Blind, Bilateral Comparison Study of the Safety and Efficacy of 10XB-101 in Adult Subjects With Bilateral Flank Adiposity
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Polidocanol (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors 10xBio
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 06 May 2019 Status changed from planning to recruiting, according to a 10xBio media release.
- 06 May 2019 Results presented in a 10xBio media release.